ArticleJournal of inflammation (London, England)2026
Resolvin D1 attenuates senescence-associated secretory phenotype independently of TGF-β-driven cardiac fibroblasts differentiation to myofibroblast.
Article in Journal of inflammation (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac fibroblasts (CF) are key regulators of myocardial inflammation through their ability to acquire senescent phenotypes and secrete inflammatory mediators. Although transforming growth factor-β (TGF-β) signaling is a central driver of myofibroblast differentiation, its contribution to inflammation-induced senescence and the senescence-associated secretory phenotype (SASP) remains poorly understood. In this study, we examined whether inflammatory stress induces senescence in adult rat CF independently of TGF-β signaling and evaluated the ability of Resolvin D1 (RvD1) to modulate the established SASP. Adult rat CF were treated with the ALK5 inhibitor SB431542 from isolation to prevent spontaneous myofibroblast differentiation. Cells were exposed to lipopolysaccharide (LPS, 1 μg/mL) under high (10%) serum conditions for 3 or 7 days. Senescence was assessed by cellular hypertrophy and SA-β-galactosidase activity. Following LPS stimulation, culture media were replaced and CF were treated with RvD1 for 48 h. Secreted cytokines, chemokines were quantified in conditioned media. LPS induced a robust senescent phenotype in CF, characterized by increased cell size and SA-β-galactosidase activity, regardless of TGF-β pathway inhibition or serum concentration. Inhibition of TGF-β signaling prevented myofibroblast differentiation but did not attenuate senescence induction. Importantly, RvD1 treatment significantly reshaped the SASP of senescent CF, reducing pro-inflammatory mediators including IL-1β, IL-6, TNF-α, and MCP-1, while preserving anti-inflammatory cytokines. These findings identify inflammatory stress as a driver of TGF-β–independent senescence in cardiac fibroblasts and highlight RvD1 as a potent modulator of senescence-associated inflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.